My legal research combines my experience as a healthcare attorney with my interest in how pharmaceutical manufacturers&rsquo
business strategies and practices influence the public&rsquo
s&rsquo
access to healthcare. To date, my research has explored these practices in the following areas: brand name manufacturers&rsquo
manipulation of citizen petitions to delay the entry of
generic drugs into the market
pharmaceutical practices that exploit less robust informed consent protections afforded human subjects enrolled in clinical trials in developing countries
FDA prohibitions on generic manufacturers to change inadequately labelled pharmaceutical products
the effectiveness of the compulsory licenses under the DOHA Declaration in terms of developing countries access to essential medicines
and economic and regula